

Attorney Docket No.: 4366.220-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Schulein et al.

Confirmation No: 2575

Serial No.: 10/007,521

Group Art Unit: 1652

Filed: December 5, 2001

Examiner: E. Slobodyansky

For: Endoglucanases

CERTIFICATE OF FACSIMILE TRANSMISSION

Commissioner for Patents
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Amendment Fee Transmittal (in duplicate)
2. Amendment

was sent to the United States Patent and Trademark Office by telefax to the attention of Examiner E. Slobodyansky, fax number (703) 746-5089.

Respectfully submitted,

Date: February 21, 2003



Elias J. Lambiris
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097

Attorney Docket No.: 4366.220-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Schulein et al.

Confirmation No: 2575

Serial No.: 10/007,521

Group Art Unit: 1652

Filed: December 5, 2001

Examiner: E. Slobodyansky

For: Endoglucanases

AMENDMENT FEE TRANSMITTAL

Commissioner for Patents
Washington, DC 20231

Sir:

Transmitted herewith is an Amendment for the above-identified application.

The fee for claims has been calculated as shown below:


Total: $26 - 20 = 6 \times 18 = \108 Independent: $1 - 3 = 0 \times 84 = \$0$

Total additional fee for claims required is \$108.

Please charge the required extension and claims fees, estimated to be \$108, to Novozymes North America, Inc., Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: February 21, 2003


Elias J. Lambiris, Reg. No. 33,728
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097

Attorney Docket No.: 4366.220-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Schulein et al.

Confirmation No: 2575

Serial No.: 10/007,521

Group Art Unit: 1652

Filed: December 5, 2001

Examiner: E. Slobodyansky

For: Endoglucanases

AMENDMENT

Commissioner for Patents
Washington, DC 20231

Sir:

H3 00*801

2021-01-10

Please amend the above-identified application as follows: 1252/0001 1007521 102105 10000000 H031848 0002/S0/E0

IN THE CLAIMS:

Please cancel claims 1, 11, 66, 84-86, 89, 91, and 97-100 without prejudice or disclaimer. Please add new claims 106-131:

106. An isolated polypeptide exhibiting endoglucanase activity, which is any of:

(a) a polypeptide having an amino acid sequence that is at least 80% homologous with the sequence of SEQ ID NO: 12;

(b) a polypeptide encoded by a DNA sequence which hybridizes with SEQ ID NO: 11 or the DNA sequence obtainable from the plasmid in *Saccharomyces cerevisiae* DSM 10081 under the following hybridization conditions: prehybridization and hybridization in a solution of 5 x SSC, 5 x Denhardt's solution, 0.5% SDS and 100 micrograms/ml of denatured sonicated salmon sperm DNA for 12 hours at about 45°C, followed by washing in 2 x SSC and 0.5% SDS at a temperature of 60°C, 65°C, 70°C, or 75°C; and

(c) a fragment of the sequence of SEQ ID NO: 12 which has endoglucanase activity.

107. The polypeptide of claim 106, which has an amino acid sequence that is at least 80% homologous with the sequence of SEQ ID NO: 12.

108. The polypeptide of claim 107, which has an amino acid sequence that is at least 90% homologous with the sequence of SEQ ID NO: 12.